Breaking Finance News

Zacks Investment Research downgraded Cidara Therapeutics Inc (NASDAQ:CDTX) to Hold in a statement released earlier today.

Showing a price of $6.95, Cidara Therapeutics Inc (NASDAQ:CDTX) traded 2.19% higher on the day. With the last stock price down -0.19% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the date range. Cidara Therapeutics Inc has recorded a 50-day average of $6.72 and a two hundred day average of $7.01. 87,697 shares of Cidara Therapeutics Inc exchanged hands, down from an avg. volume of 128,152

Zacks Investment Research has downgraded Cidara Therapeutics Inc (NASDAQ:CDTX) to Hold in a report released on 6/20/2017.

On 06/19/2017, Zacks Investment Research released a statement for Cidara Therapeutics Inc (NASDAQ:CDTX) upped the target price from $0.00 to $7.75. At the time, this indicated a possible upside of 0.14%.

See Chart Below

Cidara Therapeutics Inc (NASDAQ:CDTX)

Cidara Therapeutics Inc has with a one year low of $5.60 and a one year high of $12.95 and has a total market value of $0.

About Cidara Therapeutics Inc (NASDAQ:CDTX)

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. The Company is also developing CD201, its bispecific antimicrobial immunotherapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *